124. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy Clinical trials / Disease details
Clinical trials : 12 / Drugs : 14 - (DrugBank : 5) / Drug target genes : 6 - Drug target pathways : 23
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04753970 (ClinicalTrials.gov) | February 9, 2021 | 9/2/2021 | Retina is a Marker for Cerebrovascular Heath | Retinal Vasoreactivity is a Marker for Cerebral Small Vessel Disease Progression | Cerebral Small Vessel Diseases;Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy;Cerebral Microbleeding;Sporadic White Matter Disease | Drug: Cilostazol | Mayo Clinic | NULL | Recruiting | 18 Years | N/A | All | 40 | Phase 1/Phase 2 | United States |